ArticleThe East African health research journal2024
Dolutegravir Associated glycaemia Among Persons with HIV on Treatment at a Kenyan Referral Hospital.
Article in The East African health research journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence and Factors Associated With Hyperglycemia Among Patients on Dolutegravir-Based Antiretroviral Therapy: A Cross-Sectional Study From Central Uganda.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dolutegravir-based antiretroviral therapy is a clinically proven treatment option for persons living with the human immunodeficiency virus. However, there is emerging clinical evidence that its use may result in hyperglycaemia, but there is limited data in Africa. Objectives: To determine the prevalence of dolutegravir-associated hyperglycaemia and its covariates among Persons Living with HIV on treatment in a tertiary teaching and referral hospital in Kenya. Methods: A cross-sectional study was undertaken among adult patients who had been using dolutegravir-based regimens for at least 3 months at the comprehensive care centre in Kenyatta National Hospital. An interviewer-administered questionnaire was used to collect sociodemographic characteristics while clinical data (viral load, CD4 count) were abstracted from patients' charts. Blood samples were taken to determine random blood sugar and glycated haemoglobin levels. Data were analysed using STATA Results: We recruited 358 participants all on dolutegravir based therapy and predominantly female (62.0%). Median age was 444 (IQR 38 to 50) years. Prevalence of hyperglycaemia was 55.9%. Age above 40 years (aOR1.7; 95% CI, 1.1 to 2.7; Conclusion: Dolutegravir-based regimens are associated with hyperglycaemia among patients with advanced age and elevated body mass indices.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.